In spite of ImmunityBio Inc.’s (NASDAQ:IBRX) recent upswing, most analysts remain bearish.

As of close of business last night, ImmunityBio Inc.’s stock clocked out at $4.61, up 1.99% from its previous closing price of $4.52. In other words, the price has increased by $+0.0900 from its previous closing price. On the day, 1097892 shares were traded. IBRX stock price reached its highest trading level at $4.6400 during the session, while it also had its lowest trading level at $4.4750.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



To gain a deeper understanding of IBRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on August 03, 2022, initiated with a Buy rating and assigned the stock a target price of $8.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 3015.63.

Stock Price History:

Over the past 52 weeks, IBRX has reached a high of $7.85, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is 5.3728, while the 200-Day Moving Average is calculated to be 4.6692.

Shares Statistics:

It appears that IBRX traded 1.60M shares on average per day over the past three months and 1.5M shares per day over the past ten days. A total of 400.06M shares are outstanding, with a floating share count of 83.44M. Insiders hold about 79.16% of the company’s shares, while institutions hold 10.30% stake in the company. Shares short for IBRX as of Oct 13, 2022 were 23.49M with a Short Ratio of 22.43M, compared to 21.77M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.87% and a Short% of Float of 28.12%.

Earnings Estimates

As of right now, 2 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.26, while EPS last year was -$0.22. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.11 and low estimates of -$0.19.

Analysts are recommending an EPS of between -$0.85 and -$0.88 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$0.87, with 2 analysts recommending between -$0.85 and -$0.89.

Revenue Estimates

A total of 2 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $400k, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $250k. In the same quarter a year ago, actual revenue was $934k, down -73.20% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $11.4M in the next fiscal year. The high estimate is $20.21M and the low estimate is $2.6M. The average revenue growth estimate for next year is up 4,460.00% from the average revenue estimate for this year.